Business Context and Reporting Period
SIM Acquisition Corp. I is a Cayman Islands blank-check company formed on January 29, 2024 to pursue a business combination, with an initial focus on healthcare companies. The unaudited Form 10-Q covers the period from inception through March 31, 2024. The Company had not commenced operations or generated revenue during the period.
The July 11, 2024 initial public offering and related private placement occurred after the reporting date and are disclosed as subsequent events.
Financial Condition and Results
| Metric | March 31, 2024 / Period from inception |
|---|---|
| Total assets | $61,136, consisting entirely of deferred offering costs |
| Current liabilities | $64,600, including $27,100 of accounts payable and accrued expenses and a $37,500 related-party promissory note |
| Shareholders’ deficit | $3,464 |
| Revenue | None |
| Net loss | $28,464 |
| Basic and diluted loss per share | $0.01 loss per ordinary share |
| Cash flow from operations | $0; cash balance was $0 at March 31, 2024 |
| Debt and liquidity | No long-term debt; $37,500 related-party note outstanding at March 31, 2024 |
Formation and operating costs were the primary source of the net loss. The Sponsor paid certain formation and offering costs in exchange for founder shares and funded expenses through the related-party note.
Material Changes and Subsequent Developments
- In May 2024, the Company effected a 0.33-share dividend for each Class B ordinary share, resulting in 7,666,667 founder shares on a retroactively restated basis.
- On July 11, 2024, the Company completed its IPO of 23,000,000 units at $10.00 per unit, generating gross proceeds of $230.0 million. The underwriters fully exercised their 3,000,000-unit over-allotment option.
- Concurrent with the IPO, the Sponsor and Cantor Fitzgerald purchased 6,000,000 private placement warrants for $6.0 million in aggregate. Each warrant is exercisable for one Class A ordinary share at $11.50 per share.
- $230.0 million was placed in the Trust Account. Net proceeds after cash offering expenses and underwriting commissions were approximately $231.5 million, excluding deferred underwriting commissions of $10.95 million.
- The $37,500 related-party promissory note outstanding at March 31, 2024 was repaid upon completion of the IPO.
- Following the full exercise of the over-allotment option, no founder shares were forfeited.
Guidance, Outlook, Risks and Unusual Items
The Company has not selected a business combination target and will not generate operating revenue until after a business combination, if completed. It has a 24-month combination period from the IPO closing, extending to July 11, 2026 unless otherwise modified in accordance with governing documents and applicable requirements.
If a business combination is not completed within the permitted period, the Company must cease operations, redeem 100% of its public shares, and liquidate, subject to applicable creditor claims and other conditions. Public warrants would expire worthless upon liquidation.
- Public shareholders generally may redeem their shares for a pro rata portion of the Trust Account in connection with a proposed business combination or if the combination period expires.
- The target business or businesses must generally have an aggregate fair market value of at least 80% of the assets held in the Trust Account, subject to the governing documents.
- Management expects pre-combination liquidity requirements for legal, accounting, diligence, regulatory, insurance, administrative and general working-capital costs, but actual costs may differ materially.
- The Company expects approximately $30,000 per month in office, utilities and administrative support fees beginning July 9, 2024, continuing until a business combination or liquidation.
- A deferred underwriting commission of $10.95 million is payable from the Trust Account only if a business combination is completed.
- Management concluded that available Sponsor-related funding and the IPO proceeds provide sufficient working capital for at least one year from issuance of the financial statements, but acknowledged that completion of a business combination is not assured.
- Key risks include failure to identify or complete a suitable transaction, redemption-related funding shortfalls, dilution from additional equity or debt financing, conflicts involving the Sponsor, market and geopolitical volatility, and potential effects of the SEC’s 2024 SPAC rules.
The filing reports no material litigation, no off-balance-sheet arrangements at March 31, 2024, and no material change in internal control over financial reporting. Disclosure controls were assessed as effective at a reasonable assurance level.
Important Facts for Investors to Verify
- Confirm the post-IPO Trust Account balance, investment composition, accrued interest and any permitted withdrawals.
- Track the deadline for completing a business combination and any shareholder-approved extension.
- Review the terms and potential dilution from the 7,666,667 founder shares, 23,000,000 public shares and 6,000,000 private placement warrants.
- Assess redemption levels and the amount of additional financing that may be required to complete a transaction.
- Verify payment conditions for the $10.95 million deferred underwriting commission and the $30,000 monthly administrative support fee.
- Review any announced target, transaction valuation, projections, conflicts of interest and dilution disclosures in future filings.